Literature DB >> 16209877

Age-related gadolinium-enhancement of MRI brain lesions in multiple sclerosis.

Carla Tortorella1, Alessandra Bellacosa, Damiano Paolicelli, Aurora Fuiani, Elisabetta Di Monte, Isabella Laura Simone, Patrizia Giaquinto, Paolo Livrea, Maria Trojano.   

Abstract

There is evidence that inflammatory processes in multiple sclerosis (MS) are age-dependent. In this study we evaluated the impact of aging on gadolinium (Gd) enhancement of brain magnetic resonance imaging (MRI) lesions in MS patients. Pre- and post-contrast MRI scans, acquired using a standardized procedure by the same MRI scanner, at least 1 month far from clinical relapse or steroid treatment, were examined in 200 disease-modifying treatment free MS patients. Seventy-three patients (36.5%) showed at least one enhancing lesion. Age at MRI examination (p=0.0001), disease duration (p=0.002) and EDSS score were significantly (p=0.02) lower, whereas relapse rate in the preceding 2 years was higher (p=0.003) in patients with enhancing lesions than in patients with unenhancing scans. Multivariate logistic analysis showed that current age was the variable better predicting Gd enhancement (p=0.004). The odds ratios were 0.95 (CI: 0.92-0.98) for each year of patient's age and 0.64 (CI: 0.48-0.87) for each age decade. The main changes in enhancement risk occurred after 35 years of age. Multivariate Poisson regression model showed that relapse rate in the preceding 2 years (p<0.0001) and current age (p=0.0003) were the best predictors of the number of enhancing lesions. This information can be used to increase the statistical power of clinical trials using Gd-enhancing lesions as an outcome measure.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16209877     DOI: 10.1016/j.jns.2005.08.006

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  12 in total

Review 1.  The tension between early diagnosis and misdiagnosis of multiple sclerosis.

Authors:  Andrew J Solomon; John R Corboy
Journal:  Nat Rev Neurol       Date:  2017-08-11       Impact factor: 42.937

2.  Pittsburgh compound-B PET white matter imaging and cognitive function in late multiple sclerosis.

Authors:  Burcu Zeydan; Val J Lowe; Christopher G Schwarz; Scott A Przybelski; Nirubol Tosakulwong; Samantha M Zuk; Matthew L Senjem; Jeffrey L Gunter; Rosebud O Roberts; Michelle M Mielke; Eduardo E Benarroch; Moses Rodriguez; Mary M Machulda; Timothy G Lesnick; David S Knopman; Ronald C Petersen; Clifford R Jack; Kejal Kantarci; Orhun H Kantarci
Journal:  Mult Scler       Date:  2017-05-05       Impact factor: 6.312

3.  Age-related decreases in relapses among adults with relapsing-onset multiple sclerosis.

Authors:  Natalie A Schwehr; Karen M Kuntz; Mary Butler; Eva A Enns; Nathan D Shippee; Elaine Kingwell; Helen Tremlett; Adam F Carpenter
Journal:  Mult Scler       Date:  2019-07-29       Impact factor: 6.312

4.  Association of Age With Contrast-Enhancing Lesions Across the Multiple Sclerosis Disease Spectrum.

Authors:  Marcus W Koch; Jop Mostert; Yinan Zhang; Jerry S Wolinsky; Fred D Lublin; Eva Strijbis; Gary Cutter
Journal:  Neurology       Date:  2021-08-10       Impact factor: 11.800

5.  Clinical characteristics of a large multi-center cohort of people with multiple sclerosis over age 60.

Authors:  Le H Hua; Carrie M Hersh; Fan Tian; Ellen M Mowry; Kathryn C Fitzgerald
Journal:  Mult Scler Relat Disord       Date:  2020-11-23       Impact factor: 4.339

6.  Longitudinal study of multiple sclerosis lesions using ultra-high field (7T) multiparametric MR imaging.

Authors:  Sanjeev Chawla; Ilya Kister; Tim Sinnecker; Jens Wuerfel; Jean-Christophe Brisset; Friedemann Paul; Yulin Ge
Journal:  PLoS One       Date:  2018-09-13       Impact factor: 3.240

7.  Clinical predictors of early second event in patients with clinically isolated syndrome.

Authors:  Ellen M Mowry; Mila Pesic; Barbara Grimes; Serina R Deen; Peter Bacchetti; Emmanuelle Waubant
Journal:  J Neurol       Date:  2009-03-01       Impact factor: 4.849

8.  Intense inflammation and nerve damage in early multiple sclerosis subsides at older age: a reflection by cerebrospinal fluid biomarkers.

Authors:  Mohsen Khademi; Ann M Dring; Jonathan D Gilthorpe; Anna Wuolikainen; Faiez Al Nimer; Robert A Harris; Magnus Andersson; Lou Brundin; Fredrik Piehl; Tomas Olsson; Anders Svenningsson
Journal:  PLoS One       Date:  2013-05-07       Impact factor: 3.240

9.  Predictors of Conversion to Multiple Sclerosis in Patients with Clinical Isolated Syndrome Using the 2010 Revised McDonald Criteria.

Authors:  R Alroughani; J Al Hashel; S Lamdhade; S F Ahmed
Journal:  ISRN Neurol       Date:  2012-11-01

10.  Teriflunomide in relapsing-remitting multiple sclerosis: outcomes by age and pre-treatment status.

Authors:  Boris A Kallmann; Stefan Ries; Jennifer S Kullmann; Laura M Quint; Ulrich Engelmann; Andrew Chan
Journal:  Ther Adv Neurol Disord       Date:  2021-05-18       Impact factor: 6.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.